SciSparc unit NeuroThera closes purchase of 54% stake in CliniQuantum for CAD 9.46 million in shares

PUBT·06/04/2026 11:36:26

Listen to the news

SciSparc subsidiary NeuroThera Labs closed its purchase of about 54% of Israel-based CliniQuantum.
NeuroThera issued 56,600,000 common shares valued at about CAD 9.46 million to acquire 56,375 CliniQuantum shares.
Sellers can earn up to USD 2.5 million over three years, tied to patent filings and fundraising milestones.
CliniQuantum develops quantum-based analytics for clinical trial data, aiming to identify patient subgroups that respond to therapies.
Key asset is an exclusive worldwide license from Quantum X Labs covering a US provisional patent application in quantum Monte Carlo sampling.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number :+852 3852 8500

Monday 7:00 AM - Saturday 9:00 AM (HKT)

Service Email :service@webull.hk

Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)

Business Cooperation :marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English